Connect with us

Hi, what are you looking for?

Sunday, Jun 22, 2025
Mugglehead Investment Magazine
Alternative investment news based in Vancouver, B.C.
Optimi Health files U.S. patent for novel GMP psilocybin extraction process
Optimi Health files U.S. patent for novel GMP psilocybin extraction process
GMP psilocybin mushrooms grown at Optimi's Princeton B.C. cultivation facility. Photo by Rowan Dunne

Psychedelics

Optimi Health files U.S. patent for psilocybin extraction process

The psychedelic drug developer says the new method increases potency while maintaining the mushroom’s botanical qualities

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has filed a patent for a new method of extracting psilocybin that may reduce production costs.

Optimi announced the development on Tuesday and says the novel process required extensive research. Extracting psilocybin from mushrooms in this manner yields an extract of considerable potency that is better than synthetic psilocybin while maintaining botanical properties, according to the company.

The mushroom cultivator says its proprietary new method will help open the door for new possibilities to extract other naturally occurring compounds in the fungi.

“The establishment of new intellectual property always represents a significant milestone. All credit should be given to the team that has been instrumental in creating this inventive process and realizing this notable accomplishment,” said Optimi’s CEO Bill Ciprick.

The company congratulated the employees Orion Lekos, Jeffrey Yang, Justin Kirkland, Robin Atwal, Tony Moxam and Preston Chase for their work developing the extract.

Read more: Optimi Health disputes allegations of failing $1.2M supply agreement

Read more: Psilocybin-like drug may help people suffering from anorexia: COMPASS study

Optimi recently received a termination notice and a demand for payment from a private client because the company allegedly failed to meet its obligations under a $1.2 million psilocybin supply agreement initiated in May.

Optimi is disputing those allegations and considering legal avenues to resolve the situation.

The company also recently agreed to supply MDMA for a new training program involving the psychedelic at a series of Vancouver clinics owned by Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) and received a license to produce natural health products in May.

The Natural Health Product Site License will permit the company to produce vitamins and minerals, homeopathic remedies and other medicines.

Other British Columbia companies producing psilocybin products include Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), Apex Labs and Lucy Scientific Discovery Inc. (NASDAQ: LSDI).

Optimi shares stayed flat Tuesday at $0.19 on the Canadian Securities Exchange and have dropped by 24 per cent since the beginning of this year.

 

Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter

rowan@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Psychedelics

The state has been taking the reins when it comes to psychedelic reformation

Psychedelics

The nation has now joined Australia in this regard

Psychedelics

The biotech startup secured FDA approval for Phase I studies on its lead candidate in September

News

The nation's Senate still needs to approve the laws, but opposition is not anticipated